Abstract
In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3ng/mL (interquartile range 43-58ng/mL); in others, it was significantly (p 0.019) higher: 151ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 205.e1-205.e3 |
Rivista | Clinical Microbiology and Infection |
Volume | 21 |
Numero di pubblicazione | 2 |
DOI | |
Stato di pubblicazione | Pubblicato - 1 feb 2015 |
Pubblicato esternamente | Sì |